LAUSR

ORCID Victoria Speed https://orcid.org/0000-0001-5064-9375 Lara N. Roberts https://orcid.org/0000-0003-3871-8491 Jignesh P. Patel https://orcid.org/0000-0003-4197-8294 R E FE R E N C E S 1. Speed V, Green B, Roberts LN, et al. Fixed dose rivaroxaban can be used in extremes of bodyweight: a population pharmacokinetic analysis. J Thromb Haemost. 2020;18(9):2296-2307. 2. Kubitza D, Becka M, Zuehlsdorf M, Mueck W. Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59–7939) in healthy subjects. J Clin Pharmacol. 2007;47(2):218-226. 3. Willmann S, Zhang L, Frede M, et al. Integrated population pharmacokinetic analysis of rivaroxaban across multiple patient populations. CPT Pharmacomet Syst Pharmacol. 2018;7(5):309-320. 4. Speed V, Patel J, Roberts L, Patel R, Arya R. FIRST Registry Investigators. UK real-world experience of prescribing rivaroxaban for acute venous thromboembolism in obesity: results from the FIRST registry. Thromb Res. 2020;197:16-19. 5. Wysokinski WE, Froehling DA, Houghton DE, et al. Effectiveness and safety of apixaban and rivaroxaban for acute venous thromboembolism therapy in patients with extremes in body weight (ClinicalTrials. gov: NCT03504007). Eur J Haematol. 2020;105:484–494. 6. Quan S, Smith J, Wu C, Koshman SL, Nguyen B, Bungard TJ. Anticoagulant therapies and outcomes in obese patients with acute venous thromboembolism. Thromb Res. 2020;187:56-62. 7. Peterson ED, Ashton V, Chen Y, Wu B, Spyropoulos AC. Comparative effectiveness, safety, and costs of rivaroxaban and warfarin among morbidly obese patients with atrial fibrillation. Am Heart J. 2019;212:113-119. 8. Spyropoulos AC, Ashton V, Chen Y, Wu B, Peterson ED. Rivaroxaban versus warfarin treatment among morbidly obese patients with venous thromboembolism: comparative effectiveness, safety, and costs. Thromb Res. 2019;182:159-166. 9. Martin K, Beyer-Westendorf J, Davidson B, Huisman M, Sandset P, Moll S. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. J Thromb Haemostasi. 2016;14(6):1308–1313.